Literature DB >> 24515434

Increased TTS expression in patients with rheumatoid arthritis.

Jiaxi Chen1, Li Jun, Chen Shiyong, Hou Li, Ming Zhu, Bo Shen.   

Abstract

Immune system activation is known to be involved in the progression of rheumatoid arthritis (RA). The aim of this work was to study the imbalance expressions of indoleamine 2,3-dioxygenase (IDO) and tryptophanyl-tRNA synthetase (TTS) with RA patients. Forty-nine RA patients and 49 healthy controls were studied. The expressions of IDO and TTS were analyzed by real-time quantitative polymerase chain reaction and flow cytometry in peripheral blood mononuclear cells. The expression of TTS mRNA increased significantly in RA patients when compared with healthy controls and correlated with erythrocyte sedimentation rate (r = 0.424, P < 0.01). In addition, we found TTS increased significantly mainly in CD3(+) T cells in rheumatoid arthritis group. Increased TTS expressions from CD3(+) T cells might link to a pathogenic mechanism involved in increasing survival of autoreactive T cells in RA patients. Determination of expressions of TTS may provide a better understanding of progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24515434     DOI: 10.1007/s10238-014-0274-9

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  18 in total

Review 1.  Using an ancient tool for igniting and propagating immune tolerance: IDO as an inducer and amplifier of regulatory T cell functions.

Authors:  F Fallarino; U Grohmann
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition.

Authors:  Lingqiao Zhu; Fang Ji; Yuan Wang; Yi Zhang; Qiang Liu; Jingwu Z Zhang; Kouji Matsushima; Qi Cao; Yanyun Zhang
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

3.  Decreased IDO activity and increased TTS expression break immune tolerance in patients with immune thrombocytopenia.

Authors:  Chun-Yan Wang; Yan Shi; Ya-Nan Min; Xiao-Juan Zhu; Cheng-Shan Guo; Jun Peng; Xiao-Yuan Dong; Ping Qin; Jian-Zhi Sun; Ming Hou
Journal:  J Clin Immunol       Date:  2011-04-13       Impact factor: 8.317

Review 4.  Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease.

Authors:  W Todd Penberthy
Journal:  Curr Drug Metab       Date:  2007-04       Impact factor: 3.731

5.  Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Jeffrey R Lee; Kanchan G Jhaver; Theodore S Johnson; Derin B Keskin; Brendan Marshall; Phillip Chandler; Scott J Antonia; Russell Burgess; Craig L Slingluff; Andrew L Mellor
Journal:  Science       Date:  2002-09-13       Impact factor: 47.728

6.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

Review 7.  IDO expression by dendritic cells: tolerance and tryptophan catabolism.

Authors:  Andrew L Mellor; David H Munn
Journal:  Nat Rev Immunol       Date:  2004-10       Impact factor: 53.106

8.  Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells.

Authors:  Adriano Boasso; Jean-Philippe Herbeuval; Andrew W Hardy; Christiana Winkler; Gene M Shearer
Journal:  Blood       Date:  2004-10-05       Impact factor: 22.113

9.  Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease.

Authors:  Luigina Romani; Francesca Fallarino; Antonella De Luca; Claudia Montagnoli; Carmen D'Angelo; Teresa Zelante; Carmine Vacca; Francesco Bistoni; Maria C Fioretti; Ursula Grohmann; Brahm H Segal; Paolo Puccetti
Journal:  Nature       Date:  2008-01-10       Impact factor: 49.962

10.  Differential regulation of the human, interferon inducible tryptophanyl-tRNA synthetase by various cytokines in cell lines.

Authors:  J Fleckner; P M Martensen; A B Tolstrup; N O Kjeldgaard; J Justesen
Journal:  Cytokine       Date:  1995-01       Impact factor: 3.861

View more
  4 in total

Review 1.  Tryptophanyl-tRNA Synthetase as a Potential Therapeutic Target.

Authors:  Young Ha Ahn; Se-Chan Oh; Shengtao Zhou; Tae-Don Kim
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

2.  [Tryptophan metabolism in patients with primary immune thrombocytopenia with high dose of dexamethasone].

Authors:  Z J Li; X Q Liu; J Q Xu; Y H Liu; L M Chen; X X Chu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-03-14

Review 3.  Unique roles of tryptophanyl-tRNA synthetase in immune control and its therapeutic implications.

Authors:  Mirim Jin
Journal:  Exp Mol Med       Date:  2019-01-07       Impact factor: 8.718

4.  Tryptophan potentiates CD8+ T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation.

Authors:  Rui Qin; Chen Zhao; Chen-Ji Wang; Wei Xu; Jian-Yuan Zhao; Yan Lin; Yi-Yuan Yuan; Peng-Cheng Lin; Yao Li; Shimin Zhao; Yan Huang
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.